Accueil>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> DNA-PK>>LTURM34

LTURM34

Catalog No.GC19227

LTURM34 est un inhibiteur spécifique de la DNA-PK (IC50=34 nM). LTURM34 présente une sélectivité de 170 fois pour l'ADN-PK par rapport À PI3K. LTURM34 présente une puissante activité antiproliférative dans un large éventail de lignées cellulaires tumorales.

Products are for research use only. Not for human use. We do not sell to patients.

LTURM34 Chemical Structure

Cas No.: 1879887-96-3

Taille Prix Stock Qté
5mg
74,00 $US
En stock
10mg
121,00 $US
En stock
50mg
482,00 $US
En stock
100mg
803,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Protocol Chemical Properties Product Documents Related Products

LTURM34 is a specific DNA-PK inhibitor with an IC50 of 0.034 uM.

LTURM34 shows potent inhibition of DNA-PK with excellent selectivity over the Class I PI3K isoforms. The IC50s are 5.8 and 8.5 uM for PI3K β and δ, respectively. LTURM34 shows potent and broad ranging antiproliferative activity. LTURM34 is more consistently active against the selected cell lines (11 of 16), but at best shows 54% inhibition against the HOP-92 non-small cell lung cancer line[1].

References:
[1]. Morrison R, et al. Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8- and 6-aryl-substituted-1-3-benzoxazines. Eur J Med Chem. 2016 Mar 3;110:326-39.

Avis

Review for LTURM34

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LTURM34

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.